PGRN (at) PLGA nano compound for treating osteoarthritis as well as preparation method and application of PGRN (at) PLGA nano compound
By preparing PGRN@PLGA nanocompounds, the long-term sustained release of PGRN is achieved using nanocarriers, which solves the problems of the persistence of existing drugs and side effects, significantly improves the cartilage protection and anti-inflammatory effects, and provides new for osteoarthritis. treatment strategies.
Patent Information
- Application Number
- CN202411219900.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing drugs for treating osteoarthritis have short effects and are low in bioavailability. They cannot fundamentally improve the pathological state of damaged cartilage or block the development of osteoarthritis. Long-term use may cause cardiovascular system, liver, kidney, etc. Multiple organs have side effects.
The preparation method of PGRN@PLGA nanocompounds is adopted. By dissolving PLGA in an organic solvent and adding PGRN, sonicating and washing centrifuging, PGRN@PLGA nanocompounds are obtained, and stored in a frozen environment. The nanocarrier is used to achieve long-term effect of PGRN. Extended release.
It significantly improves the bioavailability of PGRN in the joint cavity, enhances its protection against inflammation and cartilage protection, significantly increases cartilage thickness, regulates chondrocyte regeneration and proliferation, relieves OA pain, and provides new targeted treatments for osteoarthritis. Strategy.
Smart Images

Figure CN119074697A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a PGRN@PLGA nano compound for treating osteoarthritis, and a preparation method and application thereof. Background Art
[0002] At present, the clinical treatment methods of osteoarthritis mainly include surgical treatment and drug treatment. Surgical treatment often uses joint replacement, which can usually only maintain the patient's daily life needs, but cannot meet the greater physical activity needs. Drug treatment is currently the first choice for the clinical treatment of osteoarthritis. Its main purpose is analgesia, anti-inflammatory, delaying the development of joint damage, repairing articular cartilage, and restoring joint function. Currently, commonly used non-specific drugs include antipyretic, analgesic and anti-inflammatory drugs, such as acetaminophen, ibuprofen, and cortisone. These drugs can effectively relieve pain symptoms, but cannot fundamentally improve the pathological state of damaged cartilage or block the development of osteoarthritis. Long-term use may have side effects on multiple organs such as the cardiovascular system, liver, and kidneys. The OA treatment recommended by international guidelines is also mainly aimed at the symptoms of OA, and its long-term efficacy and safety have many uncertainties.
[0003] Pathological research results of OA show that articular cartilage damage is the most important pathological change, which is mainly manifested by the degradation of articular cartilage, apoptosis of chondrocytes, and progressive degradation of extracellular matrix (ECM). Other pathological features include excessive bone growth (such as the formation of osteophytes and thickening of subchondral bone) and synovial hyperplasia. Therefore, how to repair articular cartilage damage and promote cartilage regeneration is the focus and difficulty of OA treatment. Summary of the invention
[0004] The present invention aims to provide a PGRN@PLGA nanocompound for treating osteoarthritis, and a preparation method and application thereof, in order to solve the problems that existing drugs for treating osteoarthritis have short duration of action resulting in low bioavailability, cannot fundamentally improve the pathological state of damaged cartilage or block the development of osteoarthritis, and long-term use may cause side effects on multiple organs such as the cardiovascular system, liver, and kidneys.
[0005] In order to achieve the above object, the present invention provides the following method:
[0006] Specifically, it relates to a method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis, which is characterized by:
[0007] PLGA is dissolved in an organic solvent, and PGRN is added to prepare a first solution; the first solution is added dropwise to a polyvinyl alcohol solution under low temperature conditions, and ultrasonic treatment is performed to obtain an emulsion; after ultrasonic treatment, the emulsion is added dropwise to a polyvinyl alcohol solution, and a PGRN@PLGA solution is collected to obtain the PGRN@PLGA solution; the PGRN@PLGA solution is washed and centrifuged to obtain PGRN@PLGA nanoparticles, and the PGRN@PLGA nanoparticles are stored in a freezing environment of -80°C.
[0008] In an optional embodiment, the organic solvent is ethylene dichloride.
[0009] Preferably, the first solution is added dropwise to the polyvinyl alcohol solution stirred on a magnetic stirrer under low temperature conditions; the concentration of the polyvinyl alcohol solution is 1%.
[0010] In an optional embodiment, the mass ratio of PLGA to PGRN is 9:1.
[0011] Preferably, the step of adding the first solution dropwise into the polyvinyl alcohol solution under low temperature conditions and performing ultrasonic treatment to obtain the second solution comprises: adding the first solution dropwise into the polyvinyl alcohol solution stirred on a magnetic stirrer under low temperature conditions, vortexing for 2-5 minutes at the highest speed of a vortexer, and then ultrasonically treating at 60% power, running for 3 seconds and stopping for 3 seconds, and ultrasonicating for 1-3 minutes.
[0012] Preferably, the ultrasonic process environment is an ice water environment.
[0013] Preferably, after ultrasonic treatment, the emulsion is added dropwise to the second solution under the reaction conditions of stirring at room temperature for 10-12 hours.
[0014] Preferably, the step of washing and centrifuging the PGRN@PLGA solution to obtain PGRN@PLGA nanoparticles, and preserving the PGRN@PLGA nanoparticles in a freezing environment at -80°C comprises: washing the PGRN@PLGA solution 3-5 times with distilled water; centrifuging the washed PGRN@PLGA solution at 4°C at a speed of 12000 rpm for 10 minutes, collecting the centrifuge to obtain PGRN@PLGA nanoparticles; and storing the PGRN@PLGA nanoparticles in a freezing environment at -80°C.
[0015] The present invention provides a nano compound prepared according to the preparation method of a PGRN@PLGA nano compound for treating osteoarthritis, including application of the nano compound in treating osteoarthritis.
[0016] The present invention has the following beneficial effects: the present invention enhances the long-term sustained release of PGRN in the joint cavity by utilizing nanocarriers. Thus, the bioavailability of PGRN in OA is improved, and its protective anti-inflammatory and cartilage protective effects are enhanced. The potential molecular mechanisms involved are determined; the prepared PGRN@PLGA nanoparticles can significantly increase the thickness of cartilage in the treatment of osteoarthritis, and can synthesize the metabolic protein Aggrecan and the decomposition protein MMP13. PGRN@PLGA can be used as a nano-targeted drug for regulating chondrocyte regeneration and proliferation, cartilage anabolism, and relieving OA pain, providing a new targeted treatment strategy for osteoarthritis in clinic. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following is a brief introduction to the drawings required for the specific embodiments or the description of the prior art. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn according to the actual scale.
[0018] Figure 1 It is a morphology diagram of PLGA and PGRN@PLGA provided in the embodiments of the present invention.
[0019] Figure 2 This is a diagram showing the effects of PLGA and PGRN@PLGA provided in the embodiments of the present invention on the growth and proliferation of mouse primary chondrocytes.
[0020] Figure 3 It is a comparison chart of the effects of safranin fast green staining and toluidine blue staining provided by the examples of the present invention on the evaluation of PGRN@PLGA on OA cartilage matrix in CIOA mice.
[0021] Figure 4 This is a graph of immunofluorescence staining provided in an embodiment of the present invention to detect the expression of Aggrecan and MMP13 proteins in OA cartilage of CIOA mice by PGRN@PLGA.
[0022] Figure 5 This is a diagram of the H&E staining provided in an embodiment of the present invention to detect the effect of PGRN@PLGA on the liver of CIOA mice. DETAILED DESCRIPTION
[0023] In order to make the technical personnel in the technical field better understand the scheme of the present invention, the technical scheme in the embodiment of the present invention will be clearly and completely described below in combination with the drawings in the embodiment of the present invention. Obviously, the described embodiment is only a part of the embodiment of the present invention, not all the embodiments. Based on the embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0024] The terms "first", "second", etc. in the specification and claims of the present invention and the above-mentioned drawings are used to distinguish different objects rather than to describe a specific order. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, device, product or end including a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units that are not listed, or may optionally include other steps or units inherent to these processes, methods, products or ends.
[0025] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present invention. The appearance of the phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.
[0026] At present, the clinical treatment methods of osteoarthritis mainly include surgical treatment and drug treatment. Surgical treatment often uses joint replacement, which can usually only maintain the patient's daily life needs, but cannot meet the greater physical activity needs. Drug treatment is currently the first choice for the clinical treatment of osteoarthritis. Its main purpose is analgesia, anti-inflammatory, delaying the development of joint damage, repairing articular cartilage, and restoring joint function. Currently, commonly used non-specific drugs include antipyretic, analgesic and anti-inflammatory drugs, such as acetaminophen, ibuprofen, and cortisone. These drugs can effectively relieve pain symptoms, but cannot fundamentally improve the pathological state of damaged cartilage or block the development of osteoarthritis. Long-term use may have side effects on multiple organs such as the cardiovascular system, liver, and kidneys. The OA treatment recommended by international guidelines is also mainly aimed at the symptoms of OA, and its long-term efficacy and safety have many uncertainties.
[0027] Pathological research results of OA show that articular cartilage damage is the most important pathological change, which is mainly manifested by the degradation of articular cartilage, apoptosis of chondrocytes, and progressive degradation of extracellular matrix (ECM). Other pathological features include excessive bone growth (such as the formation of osteophytes and thickening of subchondral bone) and synovial hyperplasia. Therefore, how to repair articular cartilage damage and promote cartilage regeneration is the focus and difficulty of OA treatment.
[0028] The present invention aims to provide a PGRN@PLGA nanocompound for treating osteoarthritis, and a preparation method and application thereof, in order to solve the problems that existing drugs for treating osteoarthritis have short duration of action resulting in low bioavailability, cannot fundamentally improve the pathological state of damaged cartilage or block the development of osteoarthritis, and long-term use may cause side effects on multiple organs such as the cardiovascular system, liver, and kidneys.
[0029] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0030] This embodiment provides a method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis, characterized in that:
[0031] PLGA is dissolved in an organic solvent, and PGRN is added to prepare a first solution; the first solution is added dropwise to a polyvinyl alcohol solution under low temperature conditions, and ultrasonic treatment is performed to obtain an emulsion; after ultrasonic treatment, the emulsion is added dropwise to the polyvinyl alcohol solution, and a PGRN@PLGA solution is collected to obtain the PGRN@PLGA solution; the PGRN@PLGA solution is washed and centrifuged to obtain PGRN@PLGA nanoparticles, and the PGRN@PLGA nanocompound is stored in a freezing environment of -80°C.
[0032] In an optional embodiment, the organic solvent is ethylene dichloride.
[0033] Preferably, the first solution is added dropwise to the polyvinyl alcohol solution stirred on a magnetic stirrer under low temperature conditions; the concentration of the polyvinyl alcohol solution is 1%.
[0034] In an optional embodiment, the mass ratio of PLGA to PGRN is 9:1.
[0035] Preferably, the step of adding the first solution dropwise into the polyvinyl alcohol solution under low temperature conditions and performing ultrasonic treatment to obtain the second solution comprises: adding the first solution dropwise into the polyvinyl alcohol solution stirred on a magnetic stirrer under low temperature conditions, vortexing for 2-5 minutes at the highest speed of a vortexer, and then ultrasonically treating at 60% power, running for 3 seconds and stopping for 3 seconds, and ultrasonicating for 1-3 minutes.
[0036] Preferably, the ultrasonic process environment is an ice water environment.
[0037] Preferably, after ultrasonic treatment, the emulsion is added dropwise to the polyvinyl alcohol solution under the reaction conditions of stirring at room temperature for 10-12 hours.
[0038] Preferably, the step of washing and centrifuging the PGRN@PLGA solution to obtain PGRN@PLGA nanoparticles, and preserving the PGRN@PLGA nanoparticles in a freezing environment at -80°C comprises: washing the PGRN@PLGA solution 3-5 times with distilled water; centrifuging the washed PGRN@PLGA solution at 4°C at a speed of 12000 rpmd for 10 minutes, collecting the centrifuge to obtain PGRN@PLGA nanoparticles; and storing the PGRN@PLGA nanoparticles in a freezing environment at -80°C. Specific embodiments
[0040] PGRN@PLGA was prepared by emulsification solvent evaporation method. 45 mg of PLGA35k / PLGA55K-b-PEG5K (50 / 50 wt / wt) was dissolved in dichloromethane, and 10 mg of PGRN was weighed and added to prepare a 10% w / v solution. The mixed solution (1 mL) was added dropwise to a 1% polyvinyl alcohol (PVA) solution stirred on a magnetic stirrer under low temperature conditions, vortexed at the highest speed of a vortexer for 2-5 minutes, and then ultrasonicated at 60% power, running for 3 seconds and stopping for 3 seconds, and ultrasonicated for 1-3 minutes. The container bottle was placed in ice water during the ultrasonic process. After ultrasonic treatment, the emulsion obtained by ultrasonic emulsification of the PLGA and PGRN mixture was added dropwise to 30 ml of 1% (w / v) PVA solution and stirred at room temperature for 10 hours to remove the residual organic solvent. The PGRN@PLGA was collected, washed with distilled water 3-5 times, centrifuged at 12000 rpm at 4°C for 10 minutes, and stored in a -80°C refrigerator. SEM samples were prepared and the morphology and size of PGRN@PLGA were observed using a Phenom field emission electron microscope.
[0041] Prepare SEM samples and observe the morphology and size of PGRN@PLGA using a Phenom field emission electron microscope. Figure 1 As shown, PLGA and PGRN@PLGA are oval in shape, uniform in size, and the particle size is about 150 nm;
[0042] Primary chondrocytes were isolated from the knee cartilage of neonatal rats using type II collagenase and cultured in DMEM / F12 medium containing 10% fetal bovine serum, 100 μg / mL streptomycin, and 100 U / mL penicillin. The cells were cultured in a carbon dioxide incubator at 37°C, 95% air, 5% CO2, and saturated humidity. The cells grew in an adherent manner.
[0043] After chondrocytes were plated on a 96-well plate for 24 hours, different concentrations (0, 0.625, 1.25, 2.5, 5, 10, 20, 40 and 80 μg / mL) of PLGA and PGRN@PLGA were added for 48 hours. 10 μL of CCK-8 reagent was added to each well of the 96-well plate and incubated at 37°C for one hour. All the above operations were performed under light-proof conditions. Finally, the 96-well plate was placed in an ELISA reader, and the absorbance of each well was measured at 450 nm to obtain the OD value of the absorbance; Figure 2 As shown, after 0, 0.625, 1.25, 2.5, 5, 10, 20, 40 and 80 μg / mL PLGA or PGRN@PLGA were co-incubated with mouse primary chondrocytes for 48 hours, the CCK-8 experiment was used to detect the effect of PLGA or PGRN@PLGA on the proliferation rate of mouse primary chondrocytes. The results showed that 0-80 ng / mL PLGA or PGRN@PLGA had no significant effect on the proliferation of mouse primary chondrocytes, indicating that PLGA or PGRN@PLGA had no obvious toxicity in vitro.
[0044] Thirty male mice were used to complete the in vivo experiment. After the rats were anesthetized by intraperitoneal injection of sodium pentobarbital at a concentration of 1%, their right lower limbs were disinfected, the knee joint was flexed, and a 1 ml syringe was used to insert the needle from the lower pole of the patella of the right knee joint to inject type II collagenase. The injection volume was 2U / leg. The rats were randomly divided into 3 groups: CIOA group and CIOA+PGRN, CIOA+PGRN@PLGA. One week after the intra-articular injection of iodoacetic acid, the knee joint was injected at the same time, and CIOA was injected with normal saline. Once a week for a total of 4 weeks, the knee cartilage tissue was collected 1 week after the end. The effects of PLGA or PGRN@PLGA on the cartilage of CIOA mice were evaluated by safranin fast green and toluidine staining, and the liver toxicity of mice was evaluated by H&E; Figure 3 As shown in the figure, one week after the in vivo CIOA mouse model was established, 10 μg / mL PLGA or PGRN@PLGA was injected into the joint cavity once a week for 4 weeks. The knee joint cartilage tissue was collected one week after the end of the study. The effects of PLGA or PGRN@PLGA on the cartilage of CIOA mice were evaluated by safranin fast green and toluidine staining. The results showed that compared with the CIOA group, both PLGA and PGRN@PLGA could significantly increase the cartilage thickness, and the effect of PGRN@PLGA was more significant. Figure 4As shown in the figure, one week after the in vivo CIOA mouse model was constructed, 10 μg / mL PLGA or PGRN@PLGA was injected into the joint cavity once a week for 4 weeks. The knee cartilage tissue was collected one week after the end of the injection. The effect of PLGA or PGRN@PLGA on cartilage metabolism in CIOA mice was evaluated by co-localization immunofluorescence staining of PGRN and Aggrecan or MMP13. The results showed that compared with CIOA, the expression of Aggrecan in the articular cartilage tissue of the PGRN and PGRN@PLGA groups increased, and the expression of MMP13 decreased, and the effect of PGRN@PLGA was more significant. In addition, the expression level of PGRN was the lowest in the CIOA group, and the highest in the PGRN@PLGA group; as shown in the figure, the expression level of PGRN was the lowest in the CIOA group, and the highest in the PGRN@PLGA group; as shown in the figure, the expression level of PGRN was the lowest in the CIOA group, and the expression level of PGRN was ... Figure 5 As shown, one week after the in vivo CIOA mouse model was established, 10 μg / mL PLGA or PGRN@PLGA was injected into the joint cavity once a week for 4 weeks. Liver tissue was collected one week after the end, and the pathological changes of liver tissue were detected by H&E staining. The results showed that there was no significant difference in liver staining results among the three groups, indicating that PLGA or PGRN@PLGA had no obvious toxicity in vitro.
[0045] The present invention has the following beneficial effects: the present invention enhances the long-term sustained release of PGRN in the joint cavity by utilizing nanocarriers. Thus, the bioavailability of PGRN in OA is improved, and its protective anti-inflammatory and cartilage protective effects are enhanced. The potential molecular mechanisms involved are determined; the prepared PGRN@PLGA nanoparticles can significantly increase the thickness of cartilage in the treatment of osteoarthritis, and can synthesize the metabolic protein Aggrecan and the decomposition protein MMP13. PGRN@PLGA can be used as a nano-targeted drug for regulating chondrocyte regeneration and proliferation, cartilage anabolism, and relieving OA pain, providing a new targeted treatment strategy for osteoarthritis in clinic.
[0046] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.
Claims
1. A method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis, characterized in that: The preparation method comprises the following steps: Dissolving PLGA in an organic solvent, and then adding PGRN to prepare a first solution; adding the first solution dropwise into the polyvinyl alcohol solution under low temperature conditions, and performing ultrasonic treatment to obtain an emulsion; After ultrasonic treatment, the emulsion was added dropwise to the polyvinyl alcohol solution, and the PGRN@PLGA solution was collected; The PGRN@PLGA solution is washed and centrifuged to obtain PGRN@PLGA nanocompounds, which are then stored in a freezing environment at -80°C.
2. The method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis according to claim 1, characterized in that: The organic solvent is ethylene dichloride.
3. The method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis according to claim 1, characterized in that: adding the first solution dropwise to the polyvinyl alcohol solution stirred on a magnetic stirrer under low temperature conditions; The concentration of the polyvinyl alcohol solution is 1%.
4. The method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis according to claim 1, characterized in that: The mass ratio of PLGA to PGRN was 9:
1.
5. The method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis according to claim 1, characterized in that: The step of adding the first solution dropwise into the polyvinyl alcohol solution under low temperature conditions and performing ultrasonic treatment to obtain the second solution comprises: The first solution is added dropwise to the polyvinyl alcohol solution stirred on a magnetic stirrer under low temperature conditions, and then vortexed for 2-5 minutes at the highest speed of a vortexer, and then ultrasonicated at 60% power, running for 3 seconds and stopping for 3 seconds, and ultrasonicated for 1-3 minutes.
6. The method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis according to claim 5, characterized in that: The ultrasonic process environment is an ice water environment.
7. The method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis according to claim 1, characterized in that: After ultrasonic treatment, the emulsion is added dropwise to the polyvinyl alcohol solution under the reaction conditions of stirring at room temperature for 10-12 hours.
8. The method for preparing a PGRN@PLGA nanocompound for treating osteoarthritis according to claim 1, characterized in that: The step of washing and centrifuging the PGRN@PLGA solution to obtain PGRN@PLGA nanoparticles and storing the PGRN@PLGA nanoparticles in a freezing environment of -80°C comprises: The PGRN@PLGA solution was washed 3-5 times with distilled water; The washed PGRN@PLGA solution was centrifuged at 4°C and 12000 rpm for 10 minutes, and the centrifuge was collected to obtain PGRN@PLGA nanoparticles; The PGRN@PLGA nanoparticles were stored in a freezing environment of -80°C.
9. A nano compound, characterized in that: Obtained according to the preparation method according to any one of claims 1 to 8.
10. Use of the nanocompound according to claim 9 in treating osteoarthritis.
Citation Information
Patent Citations
PLGA nanocomposite and preparation method thereof
CN106963743A
Rapamycin slow-release dosage form as well as preparation method, rapamycin slow-release injection and application
CN108771656A
Preparation method of resveratrol-loading nanocarrier and application thereof in fat reduction and liver protection
CN108888608A
Drug-loaded microgel ball, drug-loaded stent and preparation method of drug-loaded microgel ball
CN115137703A
Application of cell membrane of synovial muscle fibroblast in preparation of osteoarthritis medicine
CN117180443A
